Matches in Wikidata for { <http://www.wikidata.org/entity/Q90424840> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q90424840 description "article scientifique publié en 2018" @default.
- Q90424840 description "artículu científicu espublizáu en xunetu de 2018" @default.
- Q90424840 description "scientific article published on 23 July 2018" @default.
- Q90424840 description "wetenschappelijk artikel" @default.
- Q90424840 description "наукова стаття, опублікована в липні 2018" @default.
- Q90424840 name "Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss" @default.
- Q90424840 name "Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss" @default.
- Q90424840 type Item @default.
- Q90424840 label "Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss" @default.
- Q90424840 label "Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss" @default.
- Q90424840 prefLabel "Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss" @default.
- Q90424840 prefLabel "Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss" @default.
- Q90424840 P1433 Q90424840-304F1A1A-D891-48A4-BE83-6D73E8D2A2E0 @default.
- Q90424840 P1476 Q90424840-06E06DB4-46BC-4DBC-868D-B73E104473C0 @default.
- Q90424840 P2093 Q90424840-1B15796A-31A9-4FC3-AE8F-F4DD6E0492DA @default.
- Q90424840 P2093 Q90424840-3401DF3E-960D-4B02-A5DF-06D28F914EDB @default.
- Q90424840 P2093 Q90424840-3E6ABA1A-648C-44A8-A0AF-99A634FA2A66 @default.
- Q90424840 P2093 Q90424840-4D644A4B-3507-4D41-A878-6CB001E2E7DB @default.
- Q90424840 P2093 Q90424840-61DD914F-44C2-43C0-A2BE-31C2077B30EE @default.
- Q90424840 P2093 Q90424840-7450682B-D7DF-4786-8E14-B84C0585FBE5 @default.
- Q90424840 P2093 Q90424840-748AA71F-8157-4139-9E47-D21E548C84B1 @default.
- Q90424840 P2093 Q90424840-7E6C2F84-5966-4E17-981C-737DA373C35F @default.
- Q90424840 P2093 Q90424840-95274C25-C318-4B7D-A2A1-EFF5294362D8 @default.
- Q90424840 P2093 Q90424840-95E5AC9E-850F-4922-A6AD-70ACB1DE27FC @default.
- Q90424840 P2093 Q90424840-BE7CA986-B069-4AE9-850F-780102814378 @default.
- Q90424840 P2093 Q90424840-E2E6F479-D159-478C-A3A2-1D8F898F96A2 @default.
- Q90424840 P2093 Q90424840-EC27E56C-B44A-424C-884D-8A4F33DDD153 @default.
- Q90424840 P2093 Q90424840-F89C0816-98A2-4CE4-A243-AE3BCEDB7AF8 @default.
- Q90424840 P2093 Q90424840-FBC31F9B-34FC-446D-9DBE-C339509BF35E @default.
- Q90424840 P2860 Q90424840-9A704B17-00F4-4059-A177-8D28FDB5E044 @default.
- Q90424840 P304 Q90424840-87C0FA17-EEE2-4385-AE55-CAB90E64C090 @default.
- Q90424840 P31 Q90424840-5E8C7F37-99C2-431A-A1DF-949F8F54F1D9 @default.
- Q90424840 P356 Q90424840-97509725-08CD-4EC8-9F11-E3B37FB71AD8 @default.
- Q90424840 P433 Q90424840-4F614E6D-CC9E-4D2D-9567-A46519A60544 @default.
- Q90424840 P478 Q90424840-EA2DD633-2E6F-4AE1-A833-2C63B3F9B1FE @default.
- Q90424840 P50 Q90424840-3CD2D23A-DAB8-422F-A6EE-DC79C52632BF @default.
- Q90424840 P50 Q90424840-746B98A5-F1C2-45FD-B987-FB7D0C9E860E @default.
- Q90424840 P577 Q90424840-ADA5352C-DF22-4C4F-BB36-125A5A891B12 @default.
- Q90424840 P698 Q90424840-28C6249A-FB53-4BFD-B18B-4A310F49E85F @default.
- Q90424840 P921 Q90424840-7D4C99EE-4642-4EDB-B186-24F90E1A4F59 @default.
- Q90424840 P356 1078-0432.CCR-18-0981 @default.
- Q90424840 P698 30037818 @default.
- Q90424840 P1433 Q332253 @default.
- Q90424840 P1476 "Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss" @default.
- Q90424840 P2093 "Albert Font" @default.
- Q90424840 P2093 "Christophe Massard" @default.
- Q90424840 P2093 "Daniel J Maslyar" @default.
- Q90424840 P2093 "Daniel Nava Rodrigues" @default.
- Q90424840 P2093 "George Daniel Radavoi" @default.
- Q90424840 P2093 "Han Ma" @default.
- Q90424840 P2093 "Johann S de Bono" @default.
- Q90424840 P2093 "Kent C Shih" @default.
- Q90424840 P2093 "Na Xu" @default.
- Q90424840 P2093 "Premal H Patel" @default.
- Q90424840 P2093 "Ruth Riisnaes" @default.
- Q90424840 P2093 "Sergio Bracarda" @default.
- Q90424840 P2093 "Steven Gendreau" @default.
- Q90424840 P2093 "Viorel Jinga" @default.
- Q90424840 P2093 "Wai Y Chan" @default.
- Q90424840 P2860 Q29619905 @default.
- Q90424840 P304 "928-936" @default.
- Q90424840 P31 Q13442814 @default.
- Q90424840 P356 "10.1158/1078-0432.CCR-18-0981" @default.
- Q90424840 P433 "3" @default.
- Q90424840 P478 "25" @default.
- Q90424840 P50 Q88923334 @default.
- Q90424840 P50 Q90424835 @default.
- Q90424840 P577 "2018-07-23T00:00:00Z" @default.
- Q90424840 P698 "30037818" @default.
- Q90424840 P921 Q181257 @default.